Adalimumab in conjunction with surgery demonstrated more clinical effectiveness and improved quality of life in patients with hidradenitis suppurativa (HS) compared with outcomes in those treated with ...

People taking adalimumab (Humira) for moderate-to-severe hidradenitis suppurativa (HS) saw better results across the board when the drug was combined with a surgical intervention. That's according to ...

Please provide your email address to receive an email when new articles are posted on . Patients achieved a reduction of 19.1 in HS severity when treated with combined surgery vs. a reduction of 7.8 ...

Among adults treated with adalimumab, those with hidradenitis suppurativa (HS) showed a 53% higher risk for serious infections than adults with psoriasis, with notably increased risks for sepsis and ...

Please provide your email address to receive an email when new articles are posted on . Five patients achieved Hidradenitis Suppurativa Clinical Response with 80 mg weekly adalimumab, whereas two ...

Hidradenitis suppurativa is a painful, chronic inflammatory skin disease with few options for effective treatment. In a phase 2 trial, adalimumab, an antibody against tumor necrosis factor α, showed ...

Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as the ...

This retrospective study showed that anti–interleukin-17 drug secukinumab yielded favorable results in a small group of patients with severe hidradenitis suppurativa (HS). Researchers of a new study ...

Yuflyma (adalimumab-aaty) and its unbranded version may now be prescribed for HS in patients 12 years and older and for UV in children 2 years and older. The Food and Drug Administration (FDA) has ...